ITRM
Iterum Therapeutics Plc
NASDAQ · Pharmaceuticals
$0.30
+0.02 (+5.89%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.84M | 2.52M | 2.36M |
| Net Income | 737.1K | 595.8K | 463.7K |
| EPS | — | — | — |
| Profit Margin | 25.9% | 23.7% | 19.6% |
| Rev Growth | +5.6% | +6.9% | +16.3% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 3.14M | 2.38M | 2.35M |
| Total Equity | 9.04M | 8.10M | 7.99M |
| D/E Ratio | 0.35 | 0.29 | 0.29 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 1.27M | 1.08M | 1.08M |
| Free Cash Flow | 617.3K | 603.4K | 596.2K |